Detalhe da pesquisa
1.
Improvement of migraine depressive symptoms is not related to headache frequency: exploring the impact of anti-CGRP therapies.
Cephalalgia
; 44(2): 3331024231222923, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38307497
2.
Impact of anti-CGRP monoclonal antibodies on migraine attack accompanying symptoms: A real-world evidence study.
Cephalalgia
; 43(8): 3331024231177636, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37555331
3.
Patterns of response to anti-calcitonin gene-related peptide monoclonal antibodies during first 6 months of treatment in resistant migraine patients: Impact on outcome.
Eur J Neurol
; 30(7): 1937-1944, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37038303
4.
The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study.
J Neurol
; 268(10): 3789-3798, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-33772636